TY - JOUR
T1 - The clinical, diagnostic and treatment spectrum of seropositive and seronegative autoimmune encephalitis
T2 - Single-center cohort study of 51 cases and review of the literature
AU - Elrefaey, Ahmed
AU - Mohamedelkhair, Ahmed
AU - Fahmy, Lara
AU - Affan, Mohammad
AU - Schultz, Lonni R.
AU - Cerghet, Mirela
AU - Memon, Anza B.
N1 - Publisher Copyright:
© 2024 Japanese Society for Neuroimmunology.
PY - 2024
Y1 - 2024
N2 - Objective: Autoimmune encephalitis (AE) comprises a spectrum of inflammatory neurological syndromes characterized by immune responses to neuronal autoantigens, leading to diverse clinical manifestations, particularly behavioral and cognitive decline. Methods: This single-center retrospective study included 51 patients diagnosed with AE from 2013 to 2019 in a southeast Michigan tertiary care hospital. Patients were then divided into two groups, seropositive AE (AE+) and seronegative AE (AE−), based on antibody detection in the serum, cerebrospinal fluid or both when available. The study compares AE+ and AE− subtypes across clinical, diagnostic, and therapeutic parameters. Results: A total of 34 patients were classified as AE+, and 17 as AE−. Demographic analysis showed no significant differences in age, sex or race between the two groups. Clinical presentations varied widely, encompassing psychiatric symptoms, movement disorders, seizures and confusion; 24% patients had a prior malignancy. Laboratory assessments found diverse autoantibodies in AE+ patients' serum. Radiological and electrophysiological assessments showed no significant differences between the groups. AE− patients had higher rates of confusion compared with AE+ patients (59% vs. 18%, P = 0.004). Conclusions: This study focuses on the complexities associated with diagnosing AE, emphasizing the challenges posed by the heterogeneity of symptoms and often negative antibody test results. Rapid identification of AE, regardless of seropositivity or seronegativity, emerges as a critical factor for clinicians, facilitating the prompt initiation of immunotherapy and/or tumor removal if needed. These insights contribute to a better understanding of the landscape of this condition, offering clinicians the tools to refine their diagnostic and treatment strategies. Ultimately, the study aimed to enhance the management of AE, empowering healthcare professionals to make accurate and timely interventions for patients.
AB - Objective: Autoimmune encephalitis (AE) comprises a spectrum of inflammatory neurological syndromes characterized by immune responses to neuronal autoantigens, leading to diverse clinical manifestations, particularly behavioral and cognitive decline. Methods: This single-center retrospective study included 51 patients diagnosed with AE from 2013 to 2019 in a southeast Michigan tertiary care hospital. Patients were then divided into two groups, seropositive AE (AE+) and seronegative AE (AE−), based on antibody detection in the serum, cerebrospinal fluid or both when available. The study compares AE+ and AE− subtypes across clinical, diagnostic, and therapeutic parameters. Results: A total of 34 patients were classified as AE+, and 17 as AE−. Demographic analysis showed no significant differences in age, sex or race between the two groups. Clinical presentations varied widely, encompassing psychiatric symptoms, movement disorders, seizures and confusion; 24% patients had a prior malignancy. Laboratory assessments found diverse autoantibodies in AE+ patients' serum. Radiological and electrophysiological assessments showed no significant differences between the groups. AE− patients had higher rates of confusion compared with AE+ patients (59% vs. 18%, P = 0.004). Conclusions: This study focuses on the complexities associated with diagnosing AE, emphasizing the challenges posed by the heterogeneity of symptoms and often negative antibody test results. Rapid identification of AE, regardless of seropositivity or seronegativity, emerges as a critical factor for clinicians, facilitating the prompt initiation of immunotherapy and/or tumor removal if needed. These insights contribute to a better understanding of the landscape of this condition, offering clinicians the tools to refine their diagnostic and treatment strategies. Ultimately, the study aimed to enhance the management of AE, empowering healthcare professionals to make accurate and timely interventions for patients.
KW - anti-N-methyl-d-aspartate receptor encephalitis
KW - anti-glutamic acid decarboxylase encephalitis
KW - autoimmune encephalitis
KW - seronegative autoimmune encephalitis
KW - seropositive encephalitis
UR - http://www.scopus.com/inward/record.url?scp=85195604567&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85195604567&partnerID=8YFLogxK
U2 - 10.1111/cen3.12802
DO - 10.1111/cen3.12802
M3 - Article
AN - SCOPUS:85195604567
SN - 1759-1961
JO - Clinical and Experimental Neuroimmunology
JF - Clinical and Experimental Neuroimmunology
ER -